
Opinion|Videos|July 8, 2024
Outcomes from NATALEE and MonarchE
Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.
Advertisement
Video content above is prompted by the following:
- (Dr. O’Shaughnessy) How have the MonarchE and NATALEE trials contribute to our understanding of the optimal duration of adjuvant endocrine therapy?
- How might the difference in adjuvant therapy duration between ribociclib and abemaciclib influence discussions around risk-benefit assessments with patients considering CDK4/6i?
- (Dr. Rugo)How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
- Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
- Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure
2
5 Things to Know as Flu Season Begins
3
FDA Approves Nerandomilast for Progressive Pulmonary Fibrosis
4
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
5








































